Research Paper Volume 16, Issue 10 pp 9047—9071
Targeting PRKDC activates the efficacy of antitumor immunity while sensitizing to chemotherapy and targeted therapy in liver hepatocellular carcinoma
Figure 9. PRKDC knockdown sensitizes Huh-7 and Hep-3B to chemotherapeutic and immunotherapeutic agents. (A) Dose response curves of Gemcitabine. (B) Dose response curves of Sorafenib. (C, D) Chemokines including CCL2, CCL4, CCL5, CLCX1, CLCX8 and CLCX10 are detected using ELISA and qPCR. (E, F) Schematic representation of the CD8+ T cell migration experiment, along with the comparative migration of CD8+ T cells between the PRKDC knockdown and the control groups. (G) Dose response curves of IFN-γ in Huh-7 and Hep-3B co-cultured with CD8+ T cells. (H, I) Comparison of T cell-induced tumor cell death between PRKDC-silenced and control groups in Huh-7 or Hep-3B cells. (*P < 0.05, **P < 0.01, and ***P < 0.001 determined by two-way ANOVA test).